MNKD
Closed
Mannkind Corp
3.58
-0.16 (-4.28%)
Last Update: 01 Jul 2025 23:12:00
Yesterday: 3.74
Day's Range: 3.55 - 3.77
Send
sign up or login to leave a comment!
When Written:
4.15
MannKind Corp is a biopharmaceutical company that was founded in 1991 and is headquartered in Westlake Village, California. The company specializes in the development and commercialization of therapeutic products for patients with diabetes, pulmonary arterial hypertension, and other diseases.
MannKind's flagship product is Afrezza, an inhalable insulin used to treat diabetes. Afrezza is a rapid-acting insulin that is delivered through a small inhaler device. It was approved by the FDA in 2014 and is the only inhalable insulin currently available on the market.
In addition to Afrezza, MannKind is also developing other products, including a dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension.
MannKind has partnerships with several pharmaceutical companies, including United Therapeutics and Receptor Life Sciences, to develop and commercialize its products.
The company has faced financial challenges in the past, including a bankruptcy filing in 2016. However, it has since rebounded and continues to focus on the development and commercialization of innovative therapies for patients with unmet medical needs.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
MannKind's flagship product is Afrezza, an inhalable insulin used to treat diabetes. Afrezza is a rapid-acting insulin that is delivered through a small inhaler device. It was approved by the FDA in 2014 and is the only inhalable insulin currently available on the market.
In addition to Afrezza, MannKind is also developing other products, including a dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension.
MannKind has partnerships with several pharmaceutical companies, including United Therapeutics and Receptor Life Sciences, to develop and commercialize its products.
The company has faced financial challenges in the past, including a bankruptcy filing in 2016. However, it has since rebounded and continues to focus on the development and commercialization of innovative therapies for patients with unmet medical needs.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!








